A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
- Conditions
- Advanced Breast Cancer
- Registration Number
- NCT03047889
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Brief Summary
To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results
- Detailed Description
In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references for standardized treatment therapy, and to improve the quality of life and prolong survival time.
To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 4200
- diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014
- complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.
- no available medical record
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival status at 3 years 3 years percentage of patients still alive at 3 years
- Secondary Outcome Measures
Name Time Method PFS 3 years Progression-free survival of first line therapy
Survival status at 5 years 3 years percentage of patients still alive at 5 years
Trial Locations
- Locations (19)
The First Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, China
FuZhou General Hospital of National Miltary Command
🇨🇳Fuzhou, China
Sichuan Cancer Hospital and Institute
🇨🇳Chengdu, China
Xinjiang Medical University Cancer Hospital
🇨🇳Xinjiang, China
FuJian Provincial Cancer Hospital
🇨🇳Zhengzhou, China
Henan Cancer Hospital
🇨🇳Henan, China
Hunan Cancer Hospital
🇨🇳Hunan, China
The 307th Hospital of Military Medical Sciences
🇨🇳Beijing, China
The First Affliated Hospital of Chongqing Medical University
🇨🇳Chongqing, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Sun Yat-Sen University Cancer Center
🇨🇳Guangzhou, China
Jiangsu Provinces hospital
🇨🇳Jiangsu, China
Tumor Hospital of Yunnan Province
🇨🇳Kunming, China
General Hospital of NingXia Medical University
🇨🇳Ningxia, China
Liaoning Cancer Hospital, Zhejiang Cancer Hospital
🇨🇳Liaoning, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
The First Hospital of China Medical University
🇨🇳Shenyang, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, China
Wuhan Union Hospital
🇨🇳Wuhan, China